In oncology, the development of precision-medicine approaches has been possible owing to an improved understanding of the molecular biology of cancer, as well as impressive technical improvements in the methodology and analytical tools used. These advances have enabled investigators to understand the molecular basis of diseases and to identify molecular targets that might help to counteract them. Since the first human genome was sequenced in 1991, the amount of data generated using next-generation technologies has grown enormously 1 . Owing to the need to manage all of this valuable information, several consortia have been created, such as The Cancer Genome Atlas (TCGA), with the aim of elucidating the most frequent molecular alterations in different types of cancer 2, 3 . The central hallmarks of cancer cells have been redefined on the basis of the data generated 4 , providing a comprehensive overview of cancer-cell behaviour, and boosting the number of potential targets for therapy and associated biomarkers that might enable the prediction of treatment effectiveness. In the past decade, translational research in cancer has focused on finding molecular markers that might improve patient outcomes and quality of life. Nevertheless, besides identifying prognostic factors to predict patients who are more likely to benefit from treatment, the optimization of biomarkers that lead to the correct classification of tumours, their diagnosis and outcomes is crucial. With such an approach, the use of inefficient therapies and the resulting health-care costs will be reduced. These two aspects, tumour-type classification and treatment allocation, are of particular relevance to patients presenting with metastatic lesions of unknown origin (cancer of unknown primary (CUP)), which cannot be classified as a particular neoplasia and thus has to be treated using empirically determined chemotherapy regimens, resulting in notably poor survival rates.
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In the era of targeted therapies, accurate histopathological and molecular classification of tumours is essential, in order to administer the best tailored thera peutic strategy. Classifications based on epigenetic alterations have served this purpose. Indeed, cancer cells are characterized by a massive overall loss of DNA methylation (20-60% overall decrease in 5-methylcytosine) 5, 6 , and by the simultaneous acquisition of specific patterns of hypermethylation at CpG islands of certain promoters, which can reversibly or irreversibly alter gene function, thereby contributing to cancer progression 7, 8 . Given the importance of epigenetic mechanisms in the development of neoplasias, the utility of epigenetic characteristics in precision medicine, as well as their demonstrated usefulness in cancer diagnosis is worth highlighting. In a study published in 2012, we described the existence of different tissue-dependent epigenetic Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary Sebastián Moran 1 signatures, enabling the discrimination of tumour types on the basis of their tissue type, and not only according to their embryonic origin 9 . We subsequently applied this approach to the generation of an epigenetics-based bioinformatic tool that enables the prediction of the primary tumour of origin of a metastatic lesion classed as CUP 10 . An additional advantage of the translation of epigenetics to clinical practice comes from the nature of the material interrogated: DNA, a molecule that is stable over time, irrespective of the method of tissue fixation used and -unlike RNA -is not easily affected by external factors. Moreover, interesting progress is being made in applying epigenetic tests using novel, less-intrusive diagnostic tools, such as liquid biopsies.
Taking into account the advances in the field of epigenomics over the past decade, the purpose of this Review is to present the current knowledge of the biology and available diagnostic strategies for CUP, emphasizing the role of epigenetic signatures in clinical management, and focusing on present achievements and future perspectives. We also aim to transmit our interest in epi genetics to the health-care community, highlighting the great benefits of applying these strategies in clinical settings.
Cancer of unknown primary
Of all patients with cancer diagnosed worldwide, 3-10% present with metastases for which the primary tissue of origin cannot be determined [11] [12] [13] . Under such circumstances, the physician diagnoses cancer of unknown primary (CUP). Clinically, CUP is defined as a histologically confirmed malignancy that is incompatible with a primary neoplasm in the biopsy area, the origin of which is not clear despite a thorough clinical history, a complete physical examination, and basic complementary studies, such as those conducted with imaging techniques [14] [15] [16] . This definition, however, is not an international standard as reflected by a lack of consensus in diagnostic codes [17] [18] [19] . Of note, complete immunohistochemistry (IHC) tests or postmortem examination reveals the primary tumour in only one in four patients with CUP; the primary tumour cannot be identified in the remaining 75% of patients 20 .
Epidemiological studies involving patients with CUP are scarce and difficult to compare with each other, owing mainly to the aforementioned differences in inclusion criteria. The available studies, from the Netherlands 13 , Sweden [21] [22] [23] , Scotland 17 , Norway 24 , Australia 25 and the USA 26 , cover half a century of historical data , and highlight the distinctive trends in the management of this disease. These studies reveal an increasing incidence of CUP between 1960-1980 (16 per 100,000 individuals) 13, 17, [21] [22] [23] [24] [25] [26] . Interestingly, and despite differences depending on the start year for each of the populations analysed, a clear reduction in incidence has subsequently been observed, with a current figure of eight cases per 100,000 individuals 13, 17, [21] [22] [23] [24] [25] [26] .
The reasons for such a reduction are thought to include advances in diagnostic methods at the biological, radiological, and pathological levels; however, this decrease might also be a consequence of insufficient diagnostic inquiry, a phenomenon documented in patient populations in the USA -where, for one-fourth of patients, only a vague histological diagnosis is performed 26 . CUPs defined histologically as well-differentiated or moderately differentiated adenocarcinomas account for 50-70% of all cases, poorly differentiated carcinomas and adenocarcinomas make up another 20-30%, and the remaining cases are squamous-cell carcinomas (5-8%), or poorly differentiated or undifferentiated malignant neoplasms (2-3%) 27 . In patients with CUP, metastatic foci mainly involve the liver, in 40-50% of patients, followed by the lymph nodes (35%), lungs (31%), bones (28%), and the brain (15%) 28 . Patients with CUP rarely present before the age of 30 years, with a peak incidence at around 70 years of age. In terms of survival, the current data are very discouraging, with overall survival durations of 2.7-11 months after diagnosis and a 1-year survival of 15-20%. These values, however, represent an improvement from the median survival durations in the early 2000s, which were estimated to be only 11 weeks 13 . The current improvement is thought to be a consequence of earlier detection and advances in the management of advanced-stage neoplasias.
The clinical management of patients with CUP entails taking different steps towards deciding the appropriate treatment. Using IHC detection of markers such as vimentin, S100 family proteins, HMB45 antigen or CD45, some CUPs can be typified as non-carcinomas (sarcomas, melanomas, or lymphomas), leading to the administration of a specific treatment; however, not all non-carcinoma cases might be initially identified by IHC, and will end up being classified as poorly differentiated or undifferentiated malignant neoplasms. For 15-20% of patients, the results from either IHC or molecular tests create a strong suspicion for the presence of a primary cancer for which a specific and effective treatment exists. In such circumstances, patients should receive the corresponding site-specific treatment because, with appropriate management, long-term disease control can be achieved for 30-60% of them 16 . Data from preliminary retrospective studies have shown an improvement in survival among patients receiving site-specific therapies for the equivalent primary tumour from which the metastatic lesion originated, compared with those receiving empirical chemotherapy 29 . No indication of the origin of the primary tumour exists for the remaining patients with CUP (80-85%); their
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treatment involves an empirical chemotherapy regimen consisting of either taxanes or platinum-based agents, or a combination of the two, in conjunction with gemcitabine, which is associated with very poor therapeutic responses 30 . For this group, the median overall survival is a disheartening 6-9 months, response rates are ~20%, and the 1-year overall survival is barely 25% 31 . Within this nonspecific subset of patients, two prognostic groups can be identified on the basis of their performance status and serum lactate dehydrogenase (LDH) levels. Patients in the first group, characterized by a good performance status and stable LDH levels, have a favourable prognosis and receive the above-mentioned empirical two-drug chemotherapy regimen, which can result in a median life expectancy of 1 year. This subset of patients includes women with adenocarcinoma involving axillary nodes or with papillary adenocarcinoma of the peri toneal cavity, patients diagnosed with squamous-cell carcinoma involving cervical nodes, poorly differentiated neuroendocrine carcinomas, and adenocarcinomas with a colorectal-related immunohistochemical profile (CK-20 + , CK-7 − , and CDX-2 + ). Conversely, patients in the second group, who have elevated serum LDH levels and/or poor performance status, have a median overall survival duration of only 4 months and, depending on their performance status, receive best supportive care or chemotherapy 32 . Additional independent prognostic factors include age (median survival time of 30 weeks or 12 weeks for patients aged <60 years or >60 years, respectively, P = 0.016) 33 , number of metastatic sites (median survival time of 17 weeks or 7 weeks for patients with less or with more than three lesions, respectively, P = 0.004) 33 , ECOG-WHO performance status (patients with ECOG >1 had overall survival durations less than one-half the overall survival duration for patients with ECOG 0-1, P = 0.001) 33 , and histopathology (contrary to adenocarcinomas, squamous and neuroendocrine carcinomas have a favourable prognostic) 34 .
Diagnostic tools in CUP
In routine clinical practice, the main strategy for identifying the primary tumour in patients with CUP has been, until now, immunohistochemical analysis of tissue sections with antibodies against particular tumour-specific antigens 35 . Some of the most commonly used markers are cytokeratins 7 and 20, high and low-molecular weight keratins, and tissue-specific markers, such as homeobox protein Nkx-2.1 (also known as TTF1), mammaglobin-A, homeobox protein CDX-2, and hepato cyte-specific antigen 1 (REFS 36, 37) . A consensus panel of IHC markers has not been established and, instead, multiple panels are used [37] [38] [39] [40] [41] [42] . Unfortunately, no single specific marker exists that provides a conclusive diagnosis. Limited reproducibility is another intrinsic limitation of IHC, in part owing to the need to interpret IHC-generated preparations, which involves subjective observation. The aforementioned methodological issues have led to the poor 50-65% success rates of conventional histopathological methods in the diagnosis of metastases in patients with a known primary tumour 43 , a rate that drops to 25% when considering patients with CUP 36 .
Besides IHC, image-assisted technologies are also used to diagnose and localize the origins of CUP. CT and conventional MRI have both been used extensively to locate lesions compatible with the clinical manifestation of CUP. Nevertheless, the primary tumour might be of a small size or have regressed in patients with CUP, thus hindering a diagnosis 36 . The use of 2-[ 18 F]fluoro-2-deoxy-d-glucose (FDG)-PET-CT successfully facilitates this task [44] [45] [46] [47] [48] [49] [50] , but rarely exceeding a detection rate of 40% 51, 52 . Complementary to histological and imaging analysis, clinical protocols that take the dissemination patterns of tumours into account have been established to identify the primary origin of CUP. For example, metastases located in the liver most frequently originate in the gastrointestinal tract, lung, breast, genitourinary tract, or uvea, whereas the primary tumours of lung metastases are usually located in the breast, gastrointestinal tract, kidney, or prostate.
Not surprisingly, the routine management of patients with CUP is associated with a high degree of diagnostic uncertainty, mainly owing to the strong discrepancies between the cytological, histological, and IHC-based diagnoses performed for each patient with CUP 53 . Moreover, the idiosyncratic nature of the disease itself predisposes towards diagnostic confusion, because the tumours are very often poorly differentiated or completely undifferentiated 54 , thus hindering a correct diagnosis. This challenging situation translates directly into a low success rate of diagnostic work-up for patients with CUP, only 20-30% of whom receive a confirmed tissue-of-origin diagnosis.
Unlike IHC-based panels, in which the expression of only a small number of proteins is analysed, and whose interpretation is more subjective than qua ntitative, gene-expression-profiling studies were introduced in 2005 as a new approach to studying, in a qu antitative manner, the expression profiles of larger panels of genes typically and differentially expressed in different tumour types [55] [56] [57] [58] [59] [60] [61] . This approach enabled the prediction of the tissue of origin of CUPs by comparing their gene-expression profiles with those of a set of primary and metastatic tumours of a known origin. The application of the aforementioned approaches to primary and metastatic tumours of known origin (validation steps) has enabled the correct identification in 83-89% of patients [55] [56] [57] [58] [59] [60] [61] . Specifically, in patients with poorly differentiated and/or undifferentiated metastatic tissue of known origin, a diagnostic accuracy of 91% was described, whereas the accuracy of IHC as a diagnostic technique was only 71% 59 . These results illustrate the potential benefits of molecular diagnostic approaches in patients with CUP, demonstrating a concordance of 94% with clinicopathological features 56, 59 . Besides gene-expression-based prediction, the use of microRNA assays is another interesting approach to identifying the tissue of origin of CUPs, with results similar to those obtained with gene-expression ana lyses 62, 63 . In several studies, molecular markers (including expression profiles) have been used for the diagnosis of CUP (TABLE 1) . Of note, all molecular assays used to assign a primary tissue of origin to CUP were designed based on similarities (but not differences) between CUP and metastatic solid tumours; however, the peculiar clinical behaviour of CUP suggests the existence of molecular differences between CUP and metastases of tumours with a known primary, which have, thus far, been overlooked in diagnostic pipelines. In addition, the described assays have important limitations, such as the number of genes and patients analysed, the number of tumour types interrogated , the amount and state of preservation of the analysed clinical sample, and the overall cost of the assessment, that warrant the development of additional molecular profiling tools for CUP. To address the unmet medical need in this area, the use of epigenetic biomarkers is worth exploring 64, 65 . 
Epigenetics in cancer diagnosis
Epigenetic mechanisms are generally understood to be those that regulate gene expression at different levels without alternating the DNA sequence 64 . The epigenetic code is inherited through cell division, as well as transgenerationally 66 . In mammalian cells the pre dominant epigenetic mechanism involves covalent addition of methyl groups to the carbon-5 of cytosine moieties in DNA, although chromatin remodelling also has an important role in controlling the expression of genes and noncoding RNAs, DNA-protein interactions, suppression of the mobility of transposable elements, cellular differentiation, embryogenesis, X-chromosome inactivation, and genomic imprinting 67 . The ability of epigenetic alterations (or 'marks') to persist during development and potentially be transmitted to offspring has been proposed to be necessary to generate the wide range of phenotypes that arise from the same genotype 66 . The importance of epigenetics in cellular homeostasis is reflected by the observation that the introduction of the 'wrong type' of epigenetic marks at an inappropriate time or location is associated with the development of many diseases, including cancer 68 . In this context, an overall genomic loss of DNA methylation leads to alterations in chromosomal integrity. Specific hypomethylation marks in the promoter region of some loci can activate the transcription of growth-promoting RNAs (such as TBC1D16) 69 , or induce loss of imprinting of other genes (such as IGF2) 70 . Importantly, DNA methylation suppresses the expression of tumour-suppressor genes involved in the regulation of the cell cycle, apoptosis, DNA repair, and cell proliferation or adherence (for example, CDKN2A, CDKN2B, MLH1, MGMT, or CDH1), which might, in turn, contribute to cancer progression 7, 64 . Despite important advances in cancer diagnosis, many patients present with tumours that progress in unexpected ways or cannot be classified as known tumour subtypes. In addition, tumours with the same histopathological and genetic features show completely dissimilar behaviours -a phenomenon that could be the consequence of different epigenetic backgrounds. One example is the epigenetic reactivation of the cryptic transcript TBC1D16-47KD, which was shown to be associated with a worse prognosis (fourfold higher risk of progression) in patients with melanomas harbouring the BRAF V600E mutation, although hypomethylation of the gene encoding this RNA conferred greater sensitivity to BRAF and MEK inhibitors 69 . These results highlight how the same epigenetic alteration can have different prognostic value across different subgroups of patients with melanoma 69 . DNA-methylation profiling has revealed cancer-specific signatures of hypermethylated CpG islands, which enable the discrimination of tumour types and the prediction of response to antineoplasic treatment and patient outcomes 9, 71 . The field of pharmaco epigenetics was initiated with the original observation of the association between hypermethylation of O-6-methylguanine-DNA methyltransferase (MGMT) and a favourable tumour response to alkylating agents in patients with glioma 72, 73 , forming the basis for a test that is now used in routine clinical settings. Other epigenetic markers that have emerged after this initial report include hypermethylation of BRCA1 to predict a response to poly [ADP-ribose] polymerase (PARP) inhibitors in patients with breast and ovarian cancer 74, 75 , hypermethylation of DERL3 to predict sensitivity of colorectal cancer to glycolysis inhibitors 76 , or hypomethylation of TBC1D16 as a biomarker of higher sensitivity of melanomas to BRAF or MEK inhibitors 69 . Furthermore, a response to treatment can also be proficiently foreseen using epigenetic markers, such as the hypermethylation of SLFN11 or SRBC, which is associated with increased resistance to platinum-based drugs 77, 78 . Regarding the utility of epigenetic signatures for the accurate classification of tumours into predefined categories, aberrant DNA-hypermethylation events in cancerrelated genes, such as BRCA1, have been reported as common features of triple-negative breast cancer 79, 80 . Key epigenetic alterations involved in the initiation and progression of cancer have also been described in other neoplasias, such as acute myeloid leukaemia 81, 82 and renal-cell carcinoma 83 , highlighting their utility in early detection and differential diagnosis. The detection of hypermethylated genes in stool and blood samples is a sensitive and specific way of assessing the risk of colon cancer, and enables its early detection [84] [85] [86] . Moreover, hypermethylation events in APC, MGMT, RASSF2, and WIF1 can be detected in the plasma of patients with colon cancer with a high level of sensitivity and specificity (both 87%) 87 . Another example is the feasibility of prostate cancer diagnosis through the detection of hypermethylation of GSTP1 in tissue biopsy, urine, plasma, or sperm samples 88, 89 , with a high sensitivity and specificity (82% and 95%, respectively), and also in precursor lesions. The use of DNA methylation as a potential diagnostic biomarker for other neoplasias, such as oesophageal squamous-cell carcinoma 90 , non-small-cell lung cancer (NSCLC) 91 , and rectal cancer 92 , has also been described; for colorectal cancer [93] [94] [95] and neuroblastoma 96, 97 , the existence of several CpG islands that undergo a shared gain in DNA-methylation (conferring a so-called 'CpG island methylator phenotype') is also a useful biomarker of these malignancies.
Epigenetic approaches to CUP diagnosis
The huge advances in understanding how the epigenetic machinery functions and interacts with other proteins involved in cell transformation, the implications of these mechanisms in cell homeostasis, and how their de regulation can lead to the development of cancer, has encouraged investigators to search for DNA-methylationrelated features that, being present in CUP, might maintain the signature of the presumed primary origin.
The observation that DNA-methylation fingerprints provide important clues concerning tissue-type identity was first made in a study involving >1,000 patientderived samples using a high-throughput approach that interrogated 1,505 CpG sites, which enabled the discrimination of 24 different tumour-type-specific signatures. Until then, most of the studies characterizing DNA-methylation patterns had been restricted to examining particular genomic loci in a limited number of human samples. In this study 9 , 42 biopsy samples from patients with CUP were analysed, 29 (69%) of which were assigned a given tumour type using L1-regularized logistic regression with misclassification to create a prediction heatmap. A proposed 'foster' primary tumour was also assigned to the above described 29 CUP samples by conventional clustering analysis. A DNA-methylation-based tumour-type prediction was fully confirmed in 33 (78%) of patients at a later stage using detailed pathological analysis, in a blinded fashion 9 (TABLE 1) . Of note, the DNA-methylation patterns identified in this study 9 , across the largest spectrum of samples analysed until then, constituted a baseline for developing higher-resolution DNA-methylation maps and providing important clues about the contribution of DNA-methylation patterns to tissue uniqueness. On the basis of these results, and with the aim of developing a sufficiently robust diagnostic tool for use in clinical practice, a CUP-classifier based on DNA-methylation profiling (named EPICUP) was generated that subsequently enabled the prediction of the tissue of origin in 87% of patients 10 (TABLE 1) , representing a substantial improvement from the 25% of patients with CUP whose tissue of origin can be identified using IHC-based methods 20 . This increase could not have been achieved without the dramatic improvements made in the field of next-generation technologies for DNA-methylation analysis 98, 99 , which have generated large amounts of information, highlighting the promising role of epigenetics in the development of precision-medicine approaches 100 . In an initial discovery phase, 2,790 samples (primary tumours or metastases) from 38 tumour types of known origin were analysed using a high-throughput methylation-sequencing technology to interrogate more than 485,577 CpG sites, with 99% coverage of the genes listed in RefSeq 98 . A classifier algorithm was generated and evaluated in a secondary validation cohort that included 7,691 samples, resulting in a highly accurate predictive tool (99.6% specificity and 97.7% sensitivity) with a positive-predictive value of 88.6% -values higher than those obtained with other molecular platforms previously generated for the diagnosis of CUP 57, 61 . Both primary tumour and metastasis-derived samples were classified with equivalent precision, regardless of whether they were frozen or formalin-fixed paraffin-embedded (FFPE) samples, as had been previously demonstrated 101 . For a given biopsy, DNA-methylation data from FFPE samples were highly correlated with matched frozen biopsy samples (r = 0.97), demonstrating the equivalent performance across both preservation methods. Furthermore, the effectiveness of EPICUP in the prediction of tumour origin was demonstrated retrospectively in a international cohort of 216 patients with CUP 10 . The median age was 63 years, with most patients (60%) presenting with multiple metastases at diagnosis; adeno carcinomas or carcinomas accounted for 66% of cases, and the median overall survival duration was 9 months -values similar to those from a representative population of patients with CUP 27 . Lymph nodes were the main site of biopsy sampling at the moment of diagnosis (29%), and the tumour type most frequently predicted by EPICUP was NSCLC (in 20.6% of patients), in accordance with previously reported data obtained from autopsy-derived samples 27 (FIG. 1) .
EPICUP has proved to be a reliable tool for the determination of the source of CUP 10 (FIG. 2) ; for example, in one patient, the tissue of origin was determined at autopsy and was corroborated by IHC. Interestingly, the tissue of origin (sarcoma) was found to be the same as previously predicted by the DNA methylation-based classifier (FIG. 2a) . In other patients, EPICUP was used to guide IHC analysis with specific markers that confirmed the prediction. An unusual case was that of a male with lesions of the axillary lymph nodes, who was diagnosed with CUP after clinical and histopathological evaluation, and received empirically defined chemotherapy. At progression, the CUP was analysed using the classifier, which yielded a prediction of breast cancer that was subsequently corroborated by positive staining for mammaglobin-A on IHC, and was then treated appropriately (FIG. 2b) . As discussed previously, a clear advantage of an epigenetic-based approach is that DNA remains stable over time. Moreover, tumour-type predictions were reproducible using two DNA-methylationprofiling microarrays, 450K (REF. 98 ) and 850K (REF. 99); both were found to be useful for analytical purposes 10 . In summary, the use of DNA-methylation profiling to predict the tissue of origin of CUP is a robust strategy that can be applied in diagnosis, in conjunction with clinical and histopathological tests 20 .
Present and future challenges
The use of molecular platforms in the clinical management of patients with cancer is now a reality. Our improved knowledge of the biology and behaviour of cancer has enabled a more-accurate classification of neoplasias, resulting in optimized cancer diagnosis and prognosis, and providing guidance in the tailoring of specific therapies. A good example is that of patients with CUP, for whom this DNA-methylation-based classifier, as well as other types of molecular platforms, is or will be a key component of the diagnostic workflow and clinical management. This strategy is expected to substantially improve the quality of life and life expectancy of these patients. Nevertheless, essential and crucial steps are necessary in order to facilitate the use of such approaches in daily clinical practice, and to guarantee their inclusion in guidelines for the management of patients with CUP.
Implications for survival.
A retrospective study 29 performed in a cohort of patients with CUP with a suspected tissue of origin in the colon further supported the hypothesis that the administration of site-specific chemotherapy, consistent with the molecularly predicted tissue of origin, provides a survival benefit in patients with CUP: median survival of patients who received site-specific therapy was 27 months versus 8-11 months for a historical cohort of patients with CUP treated with empirically-determined regimens 29, 102 . Such an observation has also been supported by our retrospective study 10 , in which we observed longer overall survival durations in patients with CUP who received a treatment specific to the tissue of origin predicted on the basis of DNA-methylation profiles (n = 31), compared with those who did not receive the best available treatment for the epigenetically-predicted tissue of origin (n = 61): median survival of 13.6 months versus 6 months (P = 0.003). In a prospective nonrandomized study 103 , RT-PCRbased molecular tumour profiling was performed on biopsy specimens from patients diagnosed with CUP, and site-specific treatment consistent with the tissue of origin predicted by the assay was administered to those patients for whom a prediction was obtained (n = 194). Interestingly, the median overall survival duration was improved for the patients who received site-specific treatment compared with an historical control cohort of 396 patients with CUP who had received standard empirical chemotherapy (12.5 months versus 9.1 months). Moreover, patients whose predicted origin was a tumour type defined as being responsive to chemotherapy (for example, NSCLC, ovarian, breast, or bladder cancer), whose molecular profile was confidently predicted (defined as the probability of tissue of origin ≥80%), and who received a site-specific therapy (n = 42) had longer overall survival durations than patients with less-responsive tumour types (such as biliary tract, pancreas, gastroesophageal, liver, cervix, carcinoid, endometrium, mesothelioma, melanoma, thyroid, head and neck squamous carcinoma, adrenal, or sarcoma) and less-certain predictions (n = 58), who received empirical chemotherapy (15.4 months versus 7 months, P = 0.03) 103 . Indeed, with an increasing number of effective molecularly targeted therapies available, accurate prediction will eventually lead to the identification of additional therapeutic options for patients with CUP. This prospective clinical trial 103 was not randomized, and has not, therefore, fully answered the question of whether site-specific treatment in patients with CUP is unequivocally favourable in terms of survival. This question needs to be addressed in a randomized clinical trial in which patients with CUP are randomly assigned to receive either site-specific schedules or empirically defined chemotherapy. Such a trial approach, although technically feasible, would encounter some challenges. Firstly, some patients with CUP have cancer types that are not responsive to either standard origin-specific therapy nor empirical chemotherapy, such as tumours derived from the pancreas, liver, and biliary tract -representing 40% of the CUP cases 103 . Secondly, even for patients with CUP predicted to have originated from a chemo therapy-responsive tumour type, the standard site-specific therapy might be similar to first-line empirical therapy. Nonetheless, and as summarized by Greco 104 , enough data support the concept that a CUP diagnosis based on molecular profiling and the subsequent administration of a specific treatment according to the predicted tissue of origin improves overall survival 60, 62, 103, 105 . Future perspectives include the creation of a clinically useful diagnostic algorithm, which would incorporate pathological findings and those of molecular profiling tests -crucially, along with clinical judgment -to maximize clinical benefit and limit costs. Nevertheless, high quality prospective and randomized clinical trials must be conducted to confirm that therapy tailored to the primary tissue of origin does indeed result in improved survival durations for patients with CUP. Screening of drug-actionable alterations. An algorithm that integrates IHC, tissue-of-origin profiling, and comprehensive genomic profiling would maximize the achievement of clinically meaningful benefit while minimizing costs. As discussed previously, only patients with CUP with tumour types for which effective therapies exist can benefit from assay-based treatment decisions. The observation from several studies 60, 62, 103, 105 that patients with CUP who received a tumour-type-oriented treatment had better outcomes than those receiving nonspecific therapy might be at least partially explained by an inherently different prognosis of distinct forms of CUP, regardless of the treatment received.
Performing molecular analyses on orphan metastases in order to predict the tissue of origin could have further implications for the management of patients with CUP, because this strategy would potentially reveal the presence of any drug-actionable alteration. Patients would then be candidates for receiving targeted agents associated with better survival rates 106 . In this regard, next-generation sequencing of CUP-derived samples has revealed that many of these lesions harbour targetable genomic alterations 107, 108 (FIG. 3) . Strikingly, the incidence of mutations in the MET gene is higher in patients with CUP than in those with solid tumours of a known primary origin (~30% versus ~4%) 109 . Other clinically relevant genetic alterations that have been detected in metastases of unknown primary and are targetable include, among others, EGFR mutations, HER2 amplifications, and ALK translocations 10, 110 . Importantly, the correct determination of the primary site of origin by EPICUP and other methods could guide the selection of patients for targeted therapies. Indeed, the search for actionable mutations without knowledge of the precise cellular context might lead to some unexpected outcomes 111 . For example, the presence of a KRAS mutation in a patient with CUP predicted to be NSCLC with hylar node and brain metastases using EPICUP might have different clinical implications than those arising from the presence of the same mutation in a patient with EPICUP-diagnosed colorectal cancer. Similarly, the discovery of a BRAF V600E mutation would have different consequences for patients with CUP predicted to have arisen from melanoma, thyroid carcinoma, or colorectal cancer, because the latter would be less likely to benefit from BRAF-targeted therapy. A similar scenario would apply for epigenetic markers of drug sensitivity; for example, MGMT-promoter hypermethylation has proved to be the best predictor of a good clinical response to alkylating agents in patients with glioma 72, 73 , but only shows a modest capacity to predict sensitivity to the same agents in patients with colorectal tumours 112, 113 . This research area is newly established, and the available evidence of an association between the administration of specific targeted agents to patients with CUP and an improvement in survival remains scarce 10, 114, 115 (FIG. 4) . Patients with CUP could benefit greatly from participation in aberration-specific clinical studies, so-called 'basket trials' . Of note, the application of technologies based on next-generation sequencing can enable simultaneous interrogation of different genomic alterations (such as methylation a | CUP predicted by EPICUP to be a sarcoma: histopathological validation of the EPICUP-based diagnosis using a tumour sample after autopsy, using haematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) for vimentin, a specific marker for sarcoma, and the non-sarcoma marker S100 (negative). b | CUP predicted by EPICUP to be breast cancer. Diagnosis was confirmed by H&E staining and IHC for cytokeratins CK-7 (positive) and CK-20 (negative), and the specific breast marker mammaglobin-A (positive). c | CUP predicted to be a colon carcinoma by EPICUP, and validated using H&E staining and IHC for CK-7 (negative), CK20 (positive), and the specific colon marker homeobox protein CDX-2 (positive).
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Skin cutaneous melanoma fingerprinting or drug-actionable alterations), thus providing a more-complete picture of the molecular profile of any patient with CUP. The establishment of an international CUP consortium with a virtual tissue bank of clinically annotated CUP-derived biological material stored at several institutions would enhance the ability to perform correlative translational research. In an ideal prospective trial, patients with CUP would receive an EPICUP-based tissue of origin diagnosis, and would be randomly assigned to receive tissue-independent empirical chemotherapy versus tissue-guided optimal chemotherapy combined with targeted therapy. The end point would be overall survival in the intention-to-treat population, defined as all participating patients, including those who prematurely discontinued the study and those who are enrolled despite not meeting all selection criteria. The analysis performed in this population would address the effect of treatment under conditions closer to those of 'real-world' populations; therefore, none of the patients would be excluded and the results would be analysed according to the randomization scheme 116 . With the proposed trial design, this end point would not be subject to the confounding effect derived from the use of salvage therapies, and thus, the trial data would reach sufficient maturity at a short follow-up duration. Alternatively, EPICUP could be used in retrospective or prospective cohort studies comparing the outcomes of patients with metastatic solid tumours of a known primary with those of patients with CUPs and EPICUP-identified matched primaries. Such a cohort study could provide hints of the biological peculiarities of CUP.
Single-cell analysis and liquid biopsies
We are currently in an era of technological transition, leading to a reduction in the invasiveness and a greater personalization of the diagnostic tests used. The times of 'using a sledgehammer to crack a nut open' are over, and more-refined approaches are now gaining momentum. As an example, the DNA methylome of the whole tumour might provide very useful information, but would not be the optimal approach because each tumour has a different cellular composition 117 . The definition of single-cell profiles requires the use of minimal samples and is now feasible 118, 119 , and with the reduction in DNA-sequencing costs, its use in diagnostic testing is becoming attractive. Single-cell-sequencing approaches covering all cell populations present in the tumour have not been applied to patients with CUP, although they might enable a better understanding and provide a means of diagnosing CUP. An intermediate approach between single-cell sequencing and current molecularly based approaches is the analysis of circulating tumour cells (CTCs), which has proved valuable in providing predictive biomarkers of patient outcomes 120 , but this method does not enable the characterization of distinctive epigenetic alterations in the genomic material of CTCs, because the number of detected cells is low. In this regard, other types of epigenetic patterns, such as histone modifications, can be studied; histone-modification patterns have been described to undergo substantial aberrations in human tumours 121, 122 . Importantly, we now have powerful techniques to study not only particular histone modifications (starting with a few cells) [123] [124] [125] , but also to measure tissue-type-specific patterns of chromatin accessibility that require analysis of at least 10,000 cells 126, 127 . Another interesting advance is the analysis of circulating cell-free DNA (cfDNA) to identify alterations in biomarkers. The use of liquid biopsies (analysis of circulating tumour-derived material) will obviate or minimize the need for intrusive diagnostic biopsies, substituting them for less-intrusive blood extraction methods that can provide enough material to perform the diagnostic procedures; for example, the presence of aberrant hypermethylation of tumour-suppressor genes in serum DNA has been detectable since the late 1990s 128, 129 . Nevertheless, the introduction of more-sensitive and more-quantitative techniques for analysis of DNA methylation will facilitate its translation to the clinical setting. Examples include diffuse large-B-cell lymphoma 130 , in which detection of aberrant DAPK1 methylation in cfDNA at the time of diagnosis is a prognostic factor for long-term survival, and hepatocellular carcinoma 131 , in which methylation of VIM is an early detection biomarker. The results of studies using this approach to analyse defined CUP samples have not been reported yet, but very promising results have been obtained, in which the tissue-specific origin of cfDNA has been established 132, 133 . These proof-of-concept studies demonstrate that the tissue of origin can be determined using cfDNA. Moreover, the approach can be adapted to offer the opportunity for minimally invasive identification of cfDNA from any cell type.
Conclusions
CUP is a heterogeneous disease defined by the presence of metastatic lesions with no identified primary tumour at presentation, and is associated with extremely poor outcomes for patients, in part owing to In this patient with CUP, for whom epigenetic profiling using EPICUP predicted a non-small-cell lung cancer (NSCLC) primary, a diagnosis validated by haematoxylin and eosin (H&E) staining; immunohistochemistry for the cytokeratins CK-7 (positive) and CK-20 (negative), and the specific lung marker homeobox protein Nkx-2.1 (TTF-1; positive); and real-time PCR specific for the G719X mutation in EGFR (positive), black lines: negative controls. This patient subsequently received treatment with the EGFR inhibitor erlotinib.
the lack of information guiding the decision of the most suitable treatment. The important advances in establishing molecularly-based platforms to analyse tumourderived samples have improved our ability to determine the tumour of origin of patients with CUP; we have demonstrated 10 that these methods enable up to 87% of patients to receive a tissue-of-origin diagnosis compared with 30% using conventional diagnostic tools. These advances have been demonstrated to extend survival durations (the survival times of patients who received specific-site matched therapies were double those of patients who received empirically determined regimens) 10 . The DNA-methylation-based classifier EPICUP has enabled the correct identification of the tumour of origin in a higher proportion of patients with CUP compared with previously established approaches, and with more confidence than other gene-expression-based platforms. Importantly, the prediction of the tissue of origin can prompt the further interrogation of particular genetic alterations for which specific treatments exist (drug-actionable targets). The prospective randomized phase III GEFCAPI04 trial 134 (NCT01540058), comparing treatment determined by the gene-expression CancerTYPE ID platform 135 with empirical cisplatin plus gemcitabine chemotherapy in patients with CUP, is underway in order to assess the real effect of the use of molecular diagnostic platforms on patient survival.
EPICUP and other platforms based on gene or microRNA expression have begun to be implemented in conjunction with current diagnostic strategies, in routine clinical practice. The application of these diagnostic tools in clinical settings represents an advance in the classification of CUP, homogenizing the management of this disease in different health-care centres and improving the current poor survival of patients with this disease. Moreover, this epigenetic approach has been demonstrated to be a cost-effective strategy when compared with classic approaches consisting on imaging-based or IHC-based diagnosis, as assessed from the perspective of the USA 136 and Spanish 137 health-care systems. The suitability of methylation analysis as a diagnostic tool in clinics has been demonstrated and is derived, in part, from the molecular stability of DNA, which is easily detectable in samples obtained in routine clinical practice. The great capacity for expansion of this epigenetic-based tool could give rise to a wide range of additional applications in the arena of cancer diagnosis, in patients with CUP 138, 139 or presenting with multiple synchronous metastases 140, 141 . Overall, the development of molecular tests, such as EPICUP, is an urgent necessity for patients with cancer of uncertain origin, for whom overall survival is extremely poor. The obtained genomic and epigenomic data will be critical in the design of prospective randomized trials to show how more-precise treatments can improve the outcomes of these patients.
